ReviewEpigenomics2015
Role of epigenetic modifications in luminal breast cancer.
Review in Epigenomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Clinical Relevance of USP44 Expression and DNA Methylation Status in Breast Cancer Cell Lines, Tumor Tissues, and Circulating Tumor DNA.Breast cancer (Dove Medical Press) · 2026Article
- Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations.Current treatment options in oncology · 2025Review
- Betulin: a novel triterpenoid anti-cancerous agent targeting cervical cancer through epigenetic proteins.Molecular diversity · 2025Article
- Long Intergenic Non-Coding RNAs andNon-coding RNA · 2025Review
- Effect of Withaferin-A, Withanone, and Caffeic Acid Phenethyl Ester on DNA Methyltransferases: Potential in Epigenetic Cancer Therapy.Current topics in medicinal chemistry · 2024Article
- Updating the therapeutic role of ginsenosides in breast cancer: a bibliometrics study to an in-depth review.Frontiers in pharmacology · 2023Review
- Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer.International journal of molecular sciences · 2022Review
- Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer.Oncogene · 2022Article
- DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma.Cells · 2021Article
- DNMT1 and miRNAs: possible epigenetics footprints in electromagnetic fields utilization in oncology.Medical oncology (Northwood, London, England) · 2021Review
- Pan-cancer analysis of mWorld journal of surgical oncology · 2021Article
- OTUD7B stabilizes estrogen receptor α and promotes breast cancer cell proliferation.Cell death & disease · 2021Article
- Understanding the function of the tumor microenvironment, and compounds from marine organisms for breast cancer therapy.World journal of biological chemistry · 2021Review
- Akt regulates RSK2 to alter phosphorylation level of H2A.X in breast cancer.Oncology letters · 2021Article
- EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.Breast cancer (Tokyo, Japan) · 2021Article
- Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.BMC pharmacology & toxicology · 2021Article
- Hypomethylation of Rnase6 Promoter Enhances Proliferation and Migration of Murine Aortic Vascular Smooth Muscle Cells and Aggravates Atherosclerosis in Mice.Frontiers in bioengineering and biotechnology · 2021Article
- Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives.Cells · 2020Review
- Comprehensive analysis of prognosis-related methylated sites in breast carcinoma.Molecular genetics & genomic medicine · 2020Article
- Overexpression ofCancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Luminal breast cancers represent approximately 75% of cases. Explanations into the causes of endocrine resistance are complex and are generally ascribed to genomic mechanisms. Recently, attention has been drawn to the role of epigenetic modifications in hormone resistance. We review these here. Epigenetic modifications are reversible, heritable and include changes in DNA methylation patterns, modification of histones and altered microRNA expression levels that target the receptors or their signaling pathways. Large-scale analyses indicate distinct epigenomic profiles that distinguish breast cancers from normal and benign tissues. Taking advantage of the reversibility of epigenetic modifications, drugs that target epigenetic modifiers, given in combination with chemotherapies or endocrine therapies, may represent promising approaches to restoration of therapy responsiveness in these cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.